Naval G. Daver, MD, on the Past Year in Acute Myeloid Leukemia Research

Results from arms C and D of the phase 3 SEQUOIA trial demonstrated that zanubrutinib alone or in combination with venetoclax yields positive results in CLL/SLL subpopulations.

Experts from Georgia Cancer Center highlight ongoing retrospective studies, translational research, and other initiatives across different cancers.

The 1-year EFS with CART19 was 90% among patients with B-ALL who had 1 or more CNS relapses.

Jorge Cortes, MD, outlines the impact of imatinib in chronic myeloid leukemia and highlights future initiatives in the field.

Data from the SEQUOIA trial support the use of zanubrutinib/venetoclax in CLL or SLL regardless of del(17p)/TP53 mutation or IGHV mutational status.

Data from the BRUIN-CLL-313 study may support pirtobrutinib as a new potential standard of care for those with untreated CLL or SLL.